| name | jes-pa-pregnancy-mra-consideration |
| description | Suggests considering mineralocorticoid receptor antagonists when benefits outweigh risks in pregnant or preconception PA patients with uncontrolled hypertension and hypokalemia. Triggered when standard therapy fails and clinicians ask 'Should I consider MRAs despite pregnancy?' or when assessing risk‑benefit of MRA use. |
Evaluate MRA use in PA patients during pregnancy or preconception
STEP 1 — Gather Information
Collect pregnancy status (gestational age), blood pressure, serum potassium, current antihypertensives (especially pregnancy‑safe agents), hypertension control, hypokalemia severity, and prior response to conventional therapy.
Action: Proceed to assess whether hypertension remains uncontrolled and hypokalemia persists despite maximal tolerated pregnancy‑safe therapy.
STEP 2 — Rule In / Rule Out
If office BP ≥140/90 mm Hg and serum K+ <3.5 mmol/L despite using the highest tolerated dose of pregnancy‑safe antihypertensives (labetalol, nifedipine after 20 weeks, methyldopa) → Rule in for MRA consideration.
Otherwise → Rule out (do not initiate an MRA).
Decision: Move to stratification only when ruled in.
STEP 3 — Classify or Stratify
Stratify by gestational age:
- First trimester (<14 weeks): avoid spironolactone (anti‑androgen risk); consider eplerenone or esaxerenone if MRA deemed essential.
- Second/third trimester (≥14 weeks): spironolactone may be used with close monitoring.
Action: Select the appropriate MRA agent based on trimester and safety profile.
STEP 4 — Decide
Initiate low‑dose MRA (spironolactone 25 mg daily or eplerenone 1.25 mg daily), re‑check serum potassium and blood pressure after 5–7 days, titrate upward if needed while avoiding hyperkalemia, and do not combine eplerenone or esaxerenone with potassium supplements.
Action: Prescribe, monitor, and adjust as indicated.
Clinical Guardrails / Mimics / Pitfalls
Avoid spironolactone in the first trimester due to anti‑androgen effects; monitor for hyperkalemia especially with concomitant ACE‑I/ARB or CKD; do not use potassium supplements with eplerenone/esaxerenone; prioritize α‑methyldopa, hydralazine, labetalol, or nifedipine (after 20 weeks) before considering MRAs; counsel patients on potential fetal risks and obtain informed consent.
Concrete Clinical Example
A 32‑year‑old woman at 18 weeks gestation with biopsy‑proven PA presents with BP 152/96 mm Hg on labetalol 200 mg BID and serum K+ 2.9 mmol/L. Hypertension is uncontrolled and hypokalemia persists despite maximal labetalol. After discussing risks, spironolactone 25 mg daily is started; K+ rises to 3.8 mmol/L and BP improves to 138/86 mm Hg at one‑week follow‑up, dose is maintained with weekly K+ checks.
Source: Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021, Japan Endocrine Society, 2021
